
From London medical training to a biotech IPO and a small Houston trial, Colin Broom has built a career around the least glamorous part of medicine: getting an idea all the way through.

Before the network of more than 100 locations, there was a Seattle lab, a report on a desk, and a research technician learning how evidence can stop a crisis before it spreads.

After two decades commercializing vaccines and biopharmaceuticals, the Ophirex CEO is applying an operator’s eye to a stubborn logistical gap: what can happen between a snakebite and the hospital.

After 25 years at GSK and more than 100 transactions, the Philadelphia biotech executive made a founder's bet: the next leap in genetic medicine may depend less on the cargo than on the way it travels.
Across defense systems, diagnostics startups and a San Francisco drug-discovery company, Michael Farmer made a career of turning technical possibility into an operating business.

He trained in cell biology, learned to read biotech through markets and corporate strategy, and now leads Syntax Bio as it turns a laboratory insight into a repeatable process.

After decades moving between lab science, venture capital, public-company leadership and university innovation, Barry Selick is back inside a small biotech - carrying a career’s worth of pattern recognition into Hinge Bio’s clinical turn.

She spent nine years helping build NGM, then left for science compelling enough to begin again. At Lycia Therapeutics, Aetna Trombley has made patience, partnerships and protein clearance into an operating strategy.

Tahamtan Ahmadi built his career in the hard middle of biotechnology - where a scientific idea must survive evidence, regulation, and scale. At Genmab, his remit now stretches from discovery to medicine, and his public philosophy keeps returning to curiosity, collaboration, and patient impact.